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ABSTRACT
Objective: In the present study, we have made an attempt to the developed formulation of nanoparticles (NPs) of eprosartan mesylate (EM) 
incorporated in carboxymethyl chitosan using reverse micelle technique for the better drug delivery by improving solubility.
Methods: The NPs size and morphology were investigated by high-resolution transmission electron microscopy and field emission scanning electron 
microscopy, respectively. The physical and chemical aggregation state of eprosartan was analyzed using ultraviolet spectroscopy, and Fourier 
transforms infrared spectroscopy.
Results: To increase the solubility of eprosartan by reverse micelle technique of the drug through polymeric NPs is an alternative efficient, option for 
increasing the solubility. Eprosartan nanosuspension was successfully formulated for dissolution and bioavailability enhancement of the drug. The 
percentage drug release pattern of both formulations was compared against that of pure drug. It shows that in 10 min 39% and 17% of drug was 
released from the NPs made by RM method and microemulsion method, respectively, as compared to that of 1.3% of the pure drug. In 50 min almost 
more than half 51% of the drug was released from NPs by microemulsion method whereas only 2.5% of the drug was released from NPs containing 
the pure drug. In 120 min 67% of the drug was released from NPs by microemulsion method whereas only 5.8% of drug release was shown by NPs 
with the pure drug. We are paying attention on evaluating the influence of particle size and crystalline state on the in vitro performance of eprosartan.
Conclusion: In summary, we have developed a new approach toward the delivery of poorly water-soluble drug eprosartan by reverse micellar method. 
The particle size of NPs obtained by the reverse micellar method was significantly reduced as compared to the other method.
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INTRODUCTION
Eprosartan mesylate (EM) is an “angiotensin II receptor antagonist” 
which is used for treating high blood pressure. As compared to other 
angiotensin II receptor antagonists, eprosartan is reported to be better 
tolerated than enalapril [1]. EM antagonizes the effect of angiotensin 
II (vasoconstriction and aldosterone secretion) by blocking the 
angiotensin II receptor in vascular smooth muscle and the adrenal gland 
producing decreased blood pressure [2]. It is a BCS Class II, insoluble 
in water, antihypertensive drug having 13% oral bioavailability [3,4]. 
It has been observed and proved that the bioavailability of poorly 
soluble drug improves by nanonization, following the production of 
nanoparticles (NPs) by Sucker et al. in 1980, the nanosizing has gained a 
lot of attention [5-14]. According to Noyes Whitney equation, it has been 
observed experimentally that the reduction in particle size of a sparingly 
soluble material results in an increased rate of solution. Noyes Whitney 
is regularly used to describe the process of dissolution of solid drugs:
Dm/dt=DA (Cs−C)/h
Where the rate of change of mass dissolved (m) with time (t) is related to 
the diffusion coefficient (D) through a static layer of liquid of thickness 
h, and Cs is the equilibrium solubility and the amount dissolved at time t 
(C) in that an increase in the surface area of a drug will result in a more 
rapid dissolution process, particularly under sink conditions (where C 
<< Cs) [15].
The concept of reducing particle size to nanorange and comparing two 
different methods for the preparation of NPs has been explored in this 
experiment. Ionic gelation method and reverse micellar method were 
compared for the preparation of NPs, and their effect on particle size and 
hence solubility has been determined. Chitosan NP prepared by ionotropic 
gelation technique was first reported by Calvo and has been widely 
examined and developed by Janes. The electrostatic interaction between 
amine group of chitosan and negatively charge group of polyanion such 
as tripolyphosphate is the mechanism on which formation of chitosan NP 
is based. This technique offers a simple and mild preparation method in 
the aqueous environment. First, chitosan can be dissolved in acetic acid 
in the absence or presence of stabilizing agents, such as poloxamer, which 
can be added in the chitosan solution before or after the addition of 
polyanion. Polyanion or anionic polymers were then added, and NPs were 
spontaneously formed under mechanical stirring at room temperature. 
The size and surface charge of particles can be modified by varying the 
ratio of chitosan and stabilizer. Chitosan NP prepared by microemulsion 
technique was first developed by Maitra. This technique is based on the 
formation of chitosan NP in the aqueous core of reverse micellar droplets 
and subsequently cross-linked through glutaraldehyde. This technique 
offers a narrow size distribution of <100 nm, and the particle size can be 
controlled by varying the amount of glutaraldehyde that alters the degree 
of cross-linking. Nevertheless, some disadvantages exist such as the use 
of organic solvent, time-consuming preparation process, and complexity 
in the washing step [16].
METHODS
Drugs and chemical
Chitosan (CS) (Mw = 100,000-300,000, deacetylation degree ≥ 90% 
as determined by free amine groups) and monochloroacetic acid were 
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acquired from Sigma-Aldrich. Calcium chloride, isopropanol, methanol, 
and ethanol were obtained from Merck India; water was Millipore 
water. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
and EM were purchased from Sigma-Aldrich, USA. Dimethyl sulfoxide 
and N, N’-dimethylformamide were obtained from Merck India and 
purified by vacuum distillation. Fetal bovine serum and minimum 
essential medium were procured from Hyclone, USA, and HiMedia, 
India, respectively. Chitosan supplied by HiMedia laboratories; 
Isooctane supplied by Sigma Laboratories, Hexanol supplied by SD-fine 
chemicals, and cetyltrimethylammonium bromide (CTAB) supplied by 
SD-fine chemicals. All Chemicals are used without further purification.
Preparation of carboxymethyl chitosan (CMC)
CMC was synthesized by our formerly reported protocol with a slight 
modification. Briefly, 1.0 g of chitosan is swelled in 40 ml of 50% 
sodium hydroxide solution at 0°C overnight. Then, the chitosan is 
washed with isopropanol and dissolved in 30 ml of isopropanol and 
the monochloracetic acid (3.0 g) was dissolved in isopropanol (5 ml) 
and added into the reaction mixture dropwise for 20 min and reacted 
for 12 h at the 40°C. Then, the reaction was stopped by adding 70% 
ethyl alcohol (25 ml). The solid was filtered and rinsed in 70–90% ethyl 
alcohol, and vacuum dried at room temperature. The resulted product 
was the sodium salt of CMC [17].
Preparation of CMC NPs by ionic gelation method
CMC NPs were synthesized by ion tropic gelation of CMC solution with 
calcium chloride solution. About 0.5% CMC solution was prepared in 
distilled water. To 5 ml of this solution, 1 ml of 1.5% CaCl2 solution 
was added under constant stirring. The resulting NPs were purified 
by centrifugation for 10 min at 15,000 rpm and lyophilized [18]. 
A diagrammatical representation is given in Fig. 1 for better insight into 
the development of NCs.
Drug loading into CMC NPs
EM (1 mg/mL) is poorly water-soluble drug was dissolved in 0.05% 
10 ml glacial acetic acid solution. 10 mg CMC NPs were (per ml CMC NPs) 
introduced into the previously prepared drug solutions. The solution 
was shaken in an orbital shaker for 24 h. The suspension was then 
centrifuged at 15,000 rpm min to separate the NPs from the solutions. The 
procedure was repeated 3 times to eliminate any unloaded eprosartan 
from the suspension. The amount of loaded eprosartan was measured 
spectrophotometrically at 234 nm with a UV-1700 spectrophotometer 
(Shimadzu). The drug loading content and entrapment efficiency were 
calculated according to the following equations.
( )
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Preparation of CS NPs using microemulsion/reverse micelle 
technique
Eprosartan loaded chitosan NPs were prepared using 
cetyltrimethylammonium bromide as a surfactant, isooctane as oil, 
1-hexanol as cosolvent, eprosartan (concentration 5 mg/ml) as the 
model drug, and chitosan-eprosartan solution as the aqueous phase. 
To prepare the reversed micelles, CTAB (used in a concentration of 
5 mg/ml), isooctane oil, and cosolvent were poured into a test tube. 
The chitosan (in concentration of 5 mg/ml) in acetic acid solution, 
glutaraldehyde and eprosartan were then added to the mixture of CTAB 
and solvent under continuous stirring at room temperature.
NPs were formed in the presence of a surfactant. The system was stirred 
overnight to complete the cross-linking process, which the free amine 
group of chitosan conjugates with glutaraldehyde. The organic solvent 
is then removed by evaporation under low pressure. The formation of 
reversed micelles was inferred the mixed emulsion became transparent 
or semi-transparent. The completion of the reaction was recognized 
when the reverse micelle solvent becomes turbid. The yields obtained 
were the cross-linked chitosan NP and excess surfactant. The excess 
surfactant was then removed by precipitate with CaCl2 and then the 
precipitant was removed by centrifugation at 6000 rpm for 15 min. 
Finally, the obtained NPs were dried for 24 h in the air at the laboratory 
ambient temperature.
The eprosartan loaded chitosan NPs obtained from both the process 
were collected and compared for particle size, particle size distribution, 
zeta potential, scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), and dissolution studies.
Characterization
Particle size and zeta potential measurements
Mean particle size and its distribution were determined using dynamic 
light scattering (DLS) technique. Zeta potential was evaluated by 
measuring electrophoretic mobility of the particle using a laser-
based multiple angle electrophoresis analyzer. Eprosartan NPs were 
sufficiently diluted with deionized water to reduce the count rate up to 
100–250 kcps and analyzed by employing Malvern Zetasizer (Nano ZS, 
Malvern Instruments, UK). Observations were recorded in triplicate for 
each sample at 25°C±1°C.
Particle size measurement by SEM and TEM
Particle’s morphological characterization of eprosartan-NPs was 
executed by SEM and TEM. Samples for SEM studies were prepared by 
clinging the NPs on a double adhesive tape stuck to an aluminum stub 
and were coated with gold and palladium under an argon atmosphere 
utilizing a high-vacuum evaporator (Polaron SEM coating system). 
Samples were scanned through an electron microscope (EVO-50, ZEISS; 
UK) and photomicrographs were captured.
For TEM, a drop of optimized NPs suspension in aqueous solution was 
placed on a carbon film coated on a copper grid and freeze-dried. Then, 
NPs were observed at 80 kV using TEM TECNAI G2 20 S-TWIN (FEI, 
the Netherlands) instrument, Indian Institute of Toxicology Research, 
Lucknow.
UV and Fourier transform infrared (FTIR) studies of eprosartan CS 
NPs
The physical and chemical aggregation state of eprosartan was 
evaluated by UV and FTIR spectroscopy. The FTIR spectrums of 
eprosartan and drug-loaded chitosan NPs (freeze-dried) were obtained 
using spectrometer (Perkin Elmer). A total of 2 mg of sample was 
mixed with 100 mg of dry potassium bromide (KBr), and the mixture 
was ground into fine powder using a mortar before compressing into 
(KBr) disk under a hydraulic press at 10,000 psi. Each KBr disk was 
then scanned at 4 mm/s at a resolution of 2/cm over a wave number 
region of 400–4000/cm using IR solution (software ver. 1.10). The 
characteristics peaks of functional groups in the drug samples were 
determined and compared with pharmacopeial standards, and the 
Fig. 1: Schematic representation of synthetic procedure of 
carboxymethyl chitosan-eprosartan
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possible interactions between drug and excipients were analyzed by 
obtained data. The electronic configuration of eprosartan NPs was 
elucidated by a UV spectrophotometer (UV 1700, Shimadzu, Japan). 
Lyophilized DTX-NCs were dispersed in TDW (3.0 mL) and scanned in 
the range from 200 to 400 nm. The UV spectrum of pure eprosartan was 
taken after solubilizing it in methanol.
Evaluation studies
Dissolution studies
In vitro drug release study for optimized formulations of eprosartan 
loaded polymeric NPs was conducted in triplicate by equilibrium 
dialysis membrane method. The amount of drug release from the 
formulation was measured by a spectroscopic method. The experiment 
was performed by taking the specified volume of formulation in 
hermetically sealed dialysis membrane. The dialysis bag is suspended 
in pH 7.4 phosphate buffer saline (PBS) at 37°C being stirred at 
240 rpm speed. Samples were collected at predetermined time points, 
and subsequently, media were replenished with pH 7.4 PBS after each 
sampling to maintain sink conditions.
RESULTS AND DISCUSSION
FTIR analysis
FTIR study was conducted to characterize any possible interaction 
between drug and CMCS NPs. The characteristic peaks at 3332.21 and 
3134.11/cm (O–H stretching and N–H stretching vibrations), 2407.00/cm 
(C=N stretching vibration), and 1638.52/cm (corresponding to the C=C) 
confirm the formation of CMCS, as shown in Fig. 2.
DLS
The hydrodynamic diameter of eprosartan chitosan NPs prepared by 
reverse micellar technique is measured by DLS which is 80±10 nm, 
whereas the eprosartan chitosan NPs prepared by ionic gelation method 
were 450±10 nm. Results represent that there is a significant difference 
between the two types of NPs, which demonstrate that the NPs prepared 
by reverse micellar technique were significantly smaller in particle size. 
Zeta potential α is an electric potential of the shear plane attached to 
the moving particles in the medium, and it is generally utilized for the 
prediction of stability of nanosuspensions. The decrease in zeta potential 
value with a decrease in concentration of stabilizer may be attributed 
to the inability of stabilizer to prevent particle agglomeration at lower 
concentrations. The results of the optimized batches of eprosartan-
loaded nanosuspension prepared from both the processes depicted the 
zeta potential values of 35 mV and 50 mV of eprosartan chitosan NPs by 
ionic gelation process and microemulsion process, respectively, which 
suggested physically stable formulations were developed.
Particle size measurement by SEM and TEM (Fig. 3)
The SEM study reveals that the surface of the NPs was smooth and 
no aggregate were found from the sample used for SEM analysis. The 
particle size analysis done by TEM shows that the average particle size 
of the NPs was found to be 450 and 100 nm by ionic gelation and reverse 
micellar technique respectively. The study results are shown in Fig. 3.
Dissolution studies
The in vitro drug release pattern of NPs prepared by both the method 
against the pure drug is shown in Fig. 4. The solubility of the pure 
drug is very low because of which <10% drug is released in 140 min. 
Fig. 2: Fourier transforms infrared spectrum of eprosartan mesylate
Fig. 3: (a) Scanning electron microscopy of eprosartan 
nanoparticles; (b) transmission electron microscopy of 
eprosartan nanoparticles
Fig. 4: In vitro release studies of eprosartan nanoparticles
a b
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According to the drug release pattern of NPs by IG method, there is a 
significant increase in percentage drug release as compared to the 
pure drug while the percentage drug release of NPs by RM method is 
increased significantly as compared to that of IG method. This increase 
in percentage drug release could be attributed to the increase in 
solubility of the drug when formulated as NPs. The percentage drug 
release pattern of both the NPs shows that the NPs prepared by RM 
method have increased solubility as compared to the IG method. 
The reason behind the enhancement in the solubility could be the 
reduction in particle size. According to Noyes Whitney equation, it has 
been observed experimentally that the reduction in particle size of a 
sparingly soluble material results in an increased rate of solution.
Drug release pattern
The percentage drug release pattern of both formulations was 
compared against that of pure drug. It shows that in 10 min 39% and 
17% of the drug was released from the NPs made by RM method and 
microemulsion method, respectively, as compared to that of 1.3% of 
the pure drug. In 50 min almost more than half 51% of the drug was 
released from NPs by microemulsion method whereas only 2.5% of the 
drug was released from NPs containing pure drug. In 120 min 67% of 
the drug was released from NPs by microemulsion method whereas 
only 5.8% of drug release was shown by NPs with the pure drug.
CONCLUSION
The Chitosan NPs prepared by reverse micellar method were found 
to be more promising then ionic gelation method. The particle size of 
NPs obtained by the reverse micellar method was significantly reduced 
as compared to the other method. The reverse micellar method was 
found to be the best method for the preparation of eprosartan loaded 
chitosan NPs.
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